The cover focus of the May/June issue of Glaucoma Today focused on understanding and managing normal-tension glaucoma.
The article, "Modifying Fluid Dynamics With the Ocular Pressure Adjusting Pump", summarizes a recent public advisory committee meeting of the FDA’s Ophthalmic Devices Panel where the FSYX Ocular Pressure Adjusting Pump (Balance Ophthalmics) was discussed. During the committee meeting meeting, Leon Herndon, MD expressed the need for additional treatment options for glaucoma symptoms stating, "There is a significant unmet need for additional and adjunctive treatments to lower IOP in patients who have open-angle glaucoma and an IOP of 21 mm Hg or less. IOP increases at night in most glaucoma patients, especially those with normal daytime pressure, and that nocturnal elevation is associated with progressive vision loss."
Herndon continued, "Most therapies have minimal impact on the nocturnal IOP elevations and limited effect in patients with IOP less than 21 mm Hg. We need treatment options that can be used adjunctively to reduce patients’ pressure with normal daytime IOP and that can specifically reduce their IOP at night when [they] are most at risk of a peak in pressure."